Suraksha Diagnostics Q1 FY27: Revenue up 21% to ₹87.65 Cr, PAT surges 40% to ₹12.85 Cr
Suraksha Diagnostic Limited reported Q1 FY27 revenue of ₹87.65 crore, a 21% YoY increase. PAT grew 40% YoY to ₹12.85 crore. The company commissioned 4 new centers in Q1 and continues expansion. Its genomics vertical saw 136% YoY revenue growth.
The announcement details significant financial growth (21% revenue, 40% PAT increase) and strategic expansion (new centers, genomics growth), which are material events for investors.
The company reported strong year-on-year growth in revenue and profit, along with network expansion and significant growth in its genomics vertical, indicating positive business performance.
Suraksha Diagnostic Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a 21% year-on-year increase in revenue from operations, reaching ₹87.65 crore (₹876.5 million). Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 28% to ₹31.53 crore (₹315.3 million), with an improved EBITDA margin of 36.0%. Profit After Tax (PAT) surged by 40% to ₹12.85 crore (₹128.5 million), with a PAT margin of 14.7%.
The company also highlighted operational growth, with the number of tests performed increasing by 21% year-on-year to 2.10 million. Revenue per patient also saw a healthy increase.
During the quarter, Suraksha Diagnostic expanded its network by commissioning one hub and three spoke centers. This expansion has continued into the current quarter with the addition of two hubs and three spoke centers in July and August. The company has also extended its geographical reach by opening a hub center in Jharkhand and plans to open one in Tripura soon. Suraksha Diagnostics also reported significant growth in its genomics vertical, with revenue up 136% year-on-year to ₹1.37 crore (₹13.7 million).
The investor presentation, which details these results and the company's strategic plans, was made available on the company's website and was to be exhibited at the earnings call scheduled for August 13, 2026, at 11:30 AM IST.
What to do with a filing like this
Suraksha Diagnostic Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Suraksha Diagnostic Limited. Read the original for the full detail.